United States: How Will Trump Change The FDA?

President-elect Trump's plans for his first 100 days in office include "cutting the red tape at the FDA” and “speed[ing] the approval of life-saving medications.” Here, we consider specific steps Trump could take–without or with Congressional approval.

Adopt A Post-Marketing Approval Paradigm

One of Trump's original choices for FDA Commissioner, Jim O'Neill, is said to favor a "post-marketing approval" paradigm to shorten the time it takes new drugs to get to market. (O’Neill does not have a medical background, but did serve as Principal Associate Deputy Secretary at the Department of Health and Human Services under the George W. Bush administration.) The post-marketing approval paradigm would depart from the requirement to show safety and efficacy prior to marketing that has been in effect since the 1962 Kefauver Harris amendment to the Federal Food, Drug and Cosmetic Act, and would permit a drug to be marketed once it is shown to be safe, with efficacy demonstrated later.

This change certainly could bring drugs to market sooner, and early sales could provide an income stream to finance the most expensive stage of drug development–the clinical trials required to establish efficacy. But, will consumers–or insurers–pay for drugs that have not yet been shown to work?

It is difficult to imagine a marketplace where insurers (or the U.S. government through Medicaid) pay for drugs before effectiveness has been demonstrated. Additionally, drug companies themselves may be concerned about public relations and liability risks if a drug is not able to meet efficacy endpoints, or turns out to be less safe in larger clinical trials.

Pursue Comprehensive Modernization

Another Trump choice for FDA Commissioner, Dr. Scott Gottlieb, M.D. (who previously served as Deputy Commissioner at the FDA), does not support O’Neill’s post-marketing approval paradigm. He instead has proposed a number of alternative reforms, including:

  • Prioritizing generic approval

Gottlieb has criticized the Obama administration for making it difficult to obtain approval of generic drugs, leading to a lack of competition in the generic drug market, and higher prices for generic drugs. Gottlieb states that “[t]he FDA should prioritize applications for generic categories where competitors are exiting,” and suggests that “[c]ompanies that pursue copies of ‘abandoned’ generics could receive a voucher that gives them expedited review of another generic drug” to provide “more incentive to market copies of low-volume generics.”

  • Alleviating burdens placed on generics

Gottlieb also has criticized the FDA for “impos[ing] on generic firms many of the same costly requirements that the agency applies to branded-drug makers,” such as requirements made “in a push to reduce the risk of contamination” that “forced generic-drug makers to retool their sterile manufacturing plants and make production lines less intricate.” According to Gottlieb, instead of requiring “production lines to be dedicated to one or two drugs … [t]he FDA's safety concerns could be addressed through better quality controls and improving its inspection capabilities.”

  • Creating a different approval pathway for “complex” drugs

Gottlieb cites the EpiPen as an example of how the FDA’s treatment of “complex” drug and drug/device combinations keeps generics off the market. As Gottlieb explains, the drug in the EpiPen (epinephrine) is an old drug, but the auto-injector is protected by patents so a would-be generic would have to use a different auto-injector, but the FDA won’t let them do that:

Under the [FDA’s] interpretation of [the ANDA] rules, if a patient has to be re-trained to use a generic alternative to a branded product, then the alternative product cannot bear the same labeling as the drug it seeks to copy. As a result, it can't meet the burden of the ANDA process and be approved as a generic equivalent.

According to Gottlieb, the requirement to establish “bioequivalence” for complex drugs can be difficult or impossible when simple pharmacokinetic data is not sufficient to establish that “a copy drug has the same penetration on (and activity at) the biological site that it's targeting.” Gottlieb reasons that the current requirements were “crafted at a time when most drugs were simple, small molecule pills,” and needs to be updated:

Congress should modernize the generic drug framework to accommodate complex drugs. It could start by giving FDA more discretion to rely on a broader complement of data for evaluating generic copies to complex drugs. This could mean granting FDA the ability to ask for more than just bioequivalence and bioavailability data when it comes to making judgments around sameness as it relates to complex drugs.

  • Adopting a risk-based approach to regulation

Gottlieb would like the FDA’s efforts to be “much more risk based,” particularly in its approach to new technologies such as regenerative medicine and gene editing. Gottlieb suggests the FDA focus on “products that have the potential for latent and widely circulated risks,” and not low-risk products like smartphone apps:

I believe FDA needs to more actively consider moving its regulatory processes away from a mostly clinical orientation and toward one that ties its regulatory functions more closely to the product specific issues as well as the nature of the risk that the agency is grappling with.

For example, Gottlieb recognizes that gene-editing technologies have a potential for latent risk, but does not believe FDA should “use its pre-market requirements as a way to slow technology introduction, on the hope that time alone will reveal any potential dangers.” Rather, Gottlieb suggest “a more active approach to risk mitigation once products gain market entry, organizing this oversight based on the nature of the risk that it's trying to resolve.”

  • Strengthening regulation of laboratory tests through Clinical Labs Improvement Amendments (CLIA)

Gottlieb cites Theranos as an example of the problems with FDA oversight of laboratory tests, and suggests more oversight via CLIA instead.

FDA's review is largely focused on the diagnostic platform itself, which FDA jams into the bucket of being a medical device. …. So when it comes to diagnostics like the blood testing platform that Theranos developed, FDA focuses mostly on the tools, and not the conduct of the lab, or how the many aspects of a diagnostic service are executed.


Yet much of the risk related to diagnostics turns on how the tests are run, not just how they are built. CLIA has a long track record of inspecting labs, and overseeing how diagnostics are performed on patient samples. Ultimately, it was CLIA's oversight that surfaced the most significant problems with Theranos, not FDA's limited review of a single Theranos test.

Drawing on this example, Gottlieb concludes that “the regulation of lab tests is best left to a more robust CLIA, and not FDA,” especially “[w]hen the proper function of a novel technology is also tied closely to how it's being used.”

  • Changing drug pricing mechanisms

Gottlieb disagrees with Trump’s proposal to reduce drug prices by importing cheaper drugs, and instead would eliminate “regulations [that] force companies to launch drugs at a single price”:

We … need to make sure that branded drugs … can be priced to reflect the value they deliver to patients. That means allowing drugs to be priced according to clinical circumstances and even the stage of a disease for which they are being prescribed, and the clinical outcomes that they deliver.


Right now, drug makers are largely prevented from offering price concessions based on how a drug is used unless the all of those precise uses are explicitly spelled out in the drug's FDA approved label. So as the publication BioCentury recently noted, if a drug maker wanted to offer discounts based on a drug's ability to shorten or reduce hospital stays it can't — not unless FDA explicitly says that the drug is approved to reduce or prevent hospital stays.

Gottlieb also would like to see antitrust court decisions that favor rebate schemes that benefit everyone except patients legislatively overruled.

Gottlieb’s proposals are ambitious and would require cooperation from industry, other agencies, and Congress–not to mention time to tell if they can be effective.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.